Redeye: Xvivo Perfusion - Well-preserved value

Redeye re-initiates coverage of Xvivo with strengthened conviction following a deep dive into its clinical data and that of key competitor TransMedics, as well as target markets. While the coronavirus crisis presents some nearer-term challenges, the case is attractive in view of Xvivo’s commercial and clinical progress, strong positioning for a surgical pick-up and undemanding valuation even after the share’s recent rebound.

Read more and download the research update: https://bit.ly/36FMHNa

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/